Scarica l'app Stockscreener
138.50
0.51%
0.70
Dopo l'orario di chiusura:
138.50
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Citigroup Inc Borsa (C) Ultime notizie
Citigroup (C) Completed a Weekend Tokenized-Dollar Transfer. Can the Network Scale? - Yahoo Finance
SIG Maintained by Citigroup -- Price Target Raised to $140 - GuruFocus
Sana Biotechnology at citigroup’s biopharma back to school summit 2026: diabetes push - Investing.com
BioMarin at Citi summit: voxzogo drives growth as pipeline widens By Investing.com - Investing.com Canada
Olema Oncology at citigroup summit: palazestrant data, delays By Investing.com - Investing.com India
SYK Maintained by Citigroup -- Price Target Lowered to $360 - GuruFocus
Transcript : Novavax, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-10-2026 10 - marketscreener.com
Form FWP Citigroup Global Markets Filed by: Citigroup Global Markets Holdings Inc. - StreetInsider
Kymera Therapeutics at citigroup summit: oral immunology push gains pace By Investing.com - Investing.com India
SpyGlass Pharma at Citigroup summit: glaucoma lens nears phase iii By Investing.com - Investing.com Canada
SAB BIO at Citi summit: trial progress and a bigger t1d bet - Investing.com India
Jazz Pharmaceuticals at citigroup summit: rare-disease push gains pace By Investing.com - Investing.com India
Roivant at Citi summit: cash-rich biotech leans on three pillars - Investing.com Canada
MercadoLibre Secures $1.0 Billion 5.850% Notes Due 2036 With BofA, Citi, Goldman and Others - TradingView
Form 424B2 CITIGROUP INC - StreetInsider
Acumen at Citi biopharma summit: bets on oligomers and brain delivery - Investing.com
C Pushes Tokenized Deposits Deeper Into Asia With Japan Expansion - TradingView
Citigroup Inc. stock gains as recent earnings beat expectations - ad-hoc-news.de
Why Is Citigroup (NYES:C) Expanding in China Brokerage? - Kalkine Media
Citigroup (C) Gains on Turnaround Momentum - Yahoo Finance
Form 8K Citigroup For: 10 September By Investing.com - Investing.com Canada
Citigroup Adjusts Price Target on Cooper to $60 From $80, Keeps Neutral Rating - marketscreener.com
4 Thriving Investment Bank Behemoths to Buy With Attractive Valuation - TradingView
Citigroup Upgrades UiPath (NYSE:PATH) to "Strong-Buy" - MarketBeat
Nordnet AB And Citigroup Inc. Launch Research Portal Giving Savers Access To Research - marketscreener.com
Citigroup Inc. $C Shares Acquired by Tidal Investments LLC - MarketBeat
Citigroup Adjusts Price Target on Boston Scientific to $57 From $61, Keeps Buy Rating - marketscreener.com
Citigroup Adjusts Price Target on ResMed to $240 From $235, Keeps Neutral Rating - marketscreener.com
Citigroup Inc. $C Position Trimmed by National Pension Service - MarketBeat
WINTON GROUP Ltd Has $11.44 Million Holdings in Citigroup Inc. $C - MarketBeat
Integrated Wealth Concepts LLC Sells 10,009 Shares of Citigroup Inc. $C - MarketBeat
Engineers Gate Manager LP Lowers Stake in Citigroup Inc. $C - MarketBeat
BlueCrest Capital Management Ltd Reduces Holdings in Citigroup Inc. $C - MarketBeat
Citigroup stock heads into the open after a 1.0 percent gain - ad-hoc-news.de
Citigroup Becomes Substantial Shareholder in Lotus Resources with 5.08% Stake - Kalkine
BioAge at Citi biopharma summit: pivot to eye disease and new targets - Investing.com Canada
Citigroup's Private Bank Hires Radzinski From Bank Of America - marketscreener.com
Veradermics at citigroup summit: oral hair-loss drug nears key data - Investing.com
Citi Private Bank hires Radzinski from Bank of America - WTVB
Akamai Technologies Jumps 5.3% After Citigroup Maintains Neutral - AlphaStreet
Transcript : Cytokinetics, Incorporated Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 03:00 PM - marketscreener.com
Beam Therapeutics at Citi summit: platform gains momentum across pipeline By Investing.com - Investing.com Canada
Citigroup : Citi First Quarter, Second Quarter, Third Quarter and Fourth Quarter 2027 Earnings Calls - marketscreener.com
PII Maintained by Citigroup -- Price Target Lowered to $67 - GuruFocus
Cytokinetics at citigroup summit: hcm expansion drives growth hopes By Investing.com - Investing.com India
Transcript : Protagonist Therapeutics, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 10 - marketscreener.com
Transcript : Beam Therapeutics Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 01 - marketscreener.com
Lexicon Pharmaceuticals at Citi summit: hcm data, t1d reset - Investing.com
Transcript : Spyre Therapeutics, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 10 - marketscreener.com
Ollie’s Bargain Outlet Holdings Drops 5.7% After Citigroup Maintains Buy - AlphaStreet
Learn Why The Bull Case For Citi Stock Could Change Following China Brokerage Approval - simplywall.st
Transcript : BioAge Labs, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 11 - marketscreener.com
Vor Biopharma at Citigroup’s biopharma back to school summit: pipeline push By Investing.com - Investing.com Canada
Nuvation Bio at citigroup biopharma summit: growth rests on three pillars - Investing.com India
Lexicon Pharmaceuticals at Citi summit: hcm data, t1d reset By Investing.com - Investing.com UK
Transcript : Celcuity Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 08 - marketscreener.com
Transcript : Allogene Therapeutics, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 08 - marketscreener.com
Arcus Biosciences at Citi summit: casdatifan data loom large By Investing.com - Investing.com Canada
Transcript : EyePoint, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 08 - marketscreener.com
Arcturus Therapeutics at Citi summit: two catalysts, one pivotal year - Investing.com
Jade Biosciences at citigroup summit: fast-track bet on igan By Investing.com - Investing.com UK
Citigroup Adjusts Stryker Price Target to $360 From $399, Maintains Buy Rating - marketscreener.com
Exelixis at Citigroup summit: building a second growth engine - Investing.com
Is It Worth Investing in Citigroup (C) Based on Wall Street's Bullish Views? - Yahoo Finance
Allogene at Citi summit: mrD strategy and cash runway in focus - Investing.com
EyePoint at Citi summit: wet AMD setback, but path stays open - Investing.com India
Form FWP CITIGROUP INC Filed by: CITIGROUP INC - StreetInsider
0.34%
0.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):